Irinotecan liposome injection

DRUG10 trials

Conditions

Adjuvant TherapyAdvanced Biliary Tract CancerAdvanced Breast CancerExtrahepatic CholangiocarcinomaGallbladder CarcinomaIntrahepatic CholangiocarcinomaMetastatic Pancreatic AdenocarcinomaPancreatic Cancer

Phase 1

Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

CompletedNCT04728035

CSPC Ouyi Pharmaceutical Co., Ltd.Advanced Breast Cancer

Start: 2021-05-31End: 2024-06-05Updated: 2024-07-26

A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

CompletedNCT05383352

IpsenMetastatic Pancreatic Adenocarcinoma

Start: 2022-05-30End: 2025-04-15Updated: 2025-04-30

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Not yet recruitingNCT06259058

Tianjin Medical University Cancer Institute and HospitalPancreatic Cancer

Start: 2024-04-01End: 2027-12-01Target: 96Updated: 2024-03-15

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not yet recruitingNCT06370754

Fudan UniversityPancreatic Cancer

Start: 2024-04-30End: 2027-04-30Target: 117Updated: 2024-04-17

Phase 2

Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)

CompletedNCT04727853

CSPC Ouyi Pharmaceutical Co., Ltd.Small Cell Lung Cancer (SCLC)

Start: 2021-03-01End: 2022-04-26Updated: 2024-07-10

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

TerminatedNCT05009953

CSPC Ouyi Pharmaceutical Co., Ltd.Advanced Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma +1

Start: 2021-09-01End: 2023-01-16Updated: 2024-07-11

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

NCT05047991

CSPC Ouyi Pharmaceutical Co., Ltd.Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable

Start: 2021-10-31End: 2024-11-30Target: 153Updated: 2021-09-17

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Not yet recruitingNCT06210360

Changhai HospitalPancreatic Cancer

Start: 2024-02-01End: 2027-04-01Target: 134Updated: 2024-01-18

Phase 3

Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

CompletedNCT03088813

IpsenSmall Cell Lung Cancer

Start: 2018-04-25End: 2023-07-27Updated: 2025-02-19

Unknown Phase

Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer

RecruitingNCT06361316

Kuirong JiangAdjuvant Therapy, Pancreatic Cancer

Start: 2024-04-08End: 2028-07-31Target: 53Updated: 2024-04-11

2026-01-16

Preoperative NALIRIFOX versus upfront surgery in high-risk resectable pancreatic cancer: A randomized, multi-center trial.

Journal of Clinical Oncology2026-01-10

Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study.

2025-01-021 citations

A phase 1 study of liposomal irinotecan in patients with advanced breast cancer.

Journal of Clinical Oncology2024-06-01

A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.

Journal of Clinical Oncology2024-06-01

RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer

Cancer2022-02-2317 citations

Psychometric properties of patient reported outcome (PRO) instruments in patients with small cell lung cancer (SCLC) in RESILIENT part 1.

Journal of Clinical Oncology2021-05-20

RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.

Journal of Clinical Oncology2020-05-204 citations

RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.

Journal of Clinical Oncology2020-05-201 citations